Labetuzumab
Appearance
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized(frommouse) |
Target | carcinoembryonic antigen |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
![]() ![]() |
Labetuzumab(marketed under the trade nameCEA-CIDE) is ahumanizedIgG1monoclonal antibodyfor the treatment ofcolorectal cancer.[1]It selectively binds to carcinoembryonic cell adhesion molecule 5.[2]
Also tried in patients with MTC (medullary thyroid carcinoma) with metastasis.
This drug was developed byImmunomedics,Inc.
References
[edit]- ^"International Nonproprietary Names for Pharmaceutical Substances (INN): Labetuzumab"(PDF).WHO Drug Information.16(1): 95. 2002.
- ^"labetuzumab-SN-38 immunoconjugate IMMU-130".National Cancer Institute: NCI Dictionaries.National Institutes of Health, U.S. Department of Health and Human Services.